nach oben

Digestive Diseases and Sciences

Erschienen in:

01.09.2007 | Original Paper

X-linked Hyper-IgM Syndrome Associated with Poorly Differentiated Neuroendocrine Tumor Presenting as Obstructive Jaundice Secondary to Extensive Adenopathy

verfasst von: Nandini Nagaraj, Chukwuma Egwim, Douglas G. Adler

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Abstract

X-Linked Hyper IgM Syndrome (XHIGM) is a rare B-cell immunodeficiency disease. Patients with XHIGM are unable to switch immunoglobulin production from IgM to IgG, IgA, and IgE. Patients with XHIGM require periodic intravenous immune globulin to help prevent infections, and are also at risk for a variety of neoplasms. We describe a young man with XHIGM who presented with obstructive jaundice from malignant adenopathy from widespread, poorly differentiated neuroendocrine tumor. This has not previously been reported and represents a new association with XHIGM.

Vincent JL (1992) Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. Chest 101:810–815PubMed

Durandy A, Honjo T (2001) Human genetic defects in class-switch recombination (hyper-IgM syndromes). Curr Opin Immunol 13:543–548PubMedCrossRef

Fuleihan R, Ramesh N, Loh R, Jabara H, Rosen RS, Chatila T, Fu SM, Stamenkovic I, Geha RS (1993) Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A 90:2170–2173PubMedCrossRef

DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G (1993) CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 361:541–543PubMedCrossRef

Notarangelo LD, Peitsch MC (1996) CD40lbase: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome. Immunol Today 17:511–6PubMedCrossRef

Fuleihan RL (2001) Hyper IgM syndrome: the other side of the coin. Curr Opin Pediatr 13:528–532PubMedCrossRef

Tsuge I, Matsuoka H, Nakagawa A, Kamachi Y, Aso K, Negoro T, Ito M, Torii S, Watanabe K (1998) Necrotizing toxoplasmic encephalitis in a child with the X-linked hyper-IgM syndrome. Eur J Pediatr 157:735–737PubMedCrossRef

Cunningham CK, Bonville CA, Ochs HD, Seyama K, John PA, Rotbart HA, Weiner LB (1999) Enteroviral meningoencephalitis as a complication of X-linked hyper IgM syndrome. J Pediatr 134:584–588PubMedCrossRef

Winkelstein JA, Marinao MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME (2003) The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 82:373–384CrossRef

10.

Leiva LE, Junprasert J, Hollenbaugh D, Sorensen RU (1998) Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome. J Clin Immunol 18:283–290PubMedCrossRef

11.

Levy J, Espanel-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, Resnick I, Fasth A, Baer M, Gomez L, Sanders EA, Tabone MD, Plantaz D, Etzioni A, Monafo V, Abinun M, Hammarstrom L, Abrahamsen T, Jones A, Finn A, Klemola T, DeVries E, Sanal O, Pietsch MC, Notarangelo LD (1997) Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 131:47–54PubMedCrossRef

12.

de Gorgolas M, Erice A, Gil A, Gutierrez J, Rivas P, Hernando C, Rodriguez MC (2005) Cryptococcal meningitis in a patient with X-linked hyper-IgM1 syndrome. Scand J Infect Dis 37:526–528PubMedCrossRef

13.

Notarangelo LD, Duse M, Ugazio AG (1992) Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev 3:101–121PubMed

14.

Hayward AR, Levy J, Fachetti F, Notarangelo L, Ochs HD, Etzioni A, Bonnefoy JY, Cosyns M, Weinberg A (1997) Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 158: 977–983PubMed

15.

Rodriguez C, Carrion F, Marinovic MA, Chavez E, Preisler J, Pooley F, Futatani T, Ochs HD (2003) [X-linked hyper-IGM syndrome associated to sclerosing cholangitis and gallbladder neoplasm: clinical case]. Rev Med Chil 131:303–308PubMed

16.

Dimicoli S, Bensoussan D, Latger-Cannard V, Straczek J, Antunes L, Mainard L, Dao A, Barbe F, Araujo C, Clement L, Feugier P, Lecompte T, Stoltz JF, Bordigoni P (2003) Complete recovery from Cryptosporidium parvum infection with gastroenteritis and sclerosing cholangitis after successful bone marrow transplantation in two brothers with X-linked hyper-IgM syndrome. Bone Marrow Transplant 32:733–737PubMedCrossRef

17.

Lin SC, Shyur SD, Ma YC, Huang LH, Lee HC, Lee WI (2005) Recurrent acalculous cholecystitis and sclerosing cholangitis in a patient with X-linked hyper-immunoglobulin M syndrome. J Formos Med Assoc 104:421–426PubMed

18.

Zirkin HJ, Levy J, Katchko L (1996) Small cell undifferentiated carcinoma of the colon associated with hepatocellular carcinoma in an immunodeficient patient. Hum Pathol 27:992–996PubMedCrossRef

19.

Gallerani I, Innoncenti DD, Coronella G, Berti S, Amato L, Moretti S, Fabbri P (2004) Cutaneous sarcoid-like granulomas in a patient with X-linked hyper-IgM syndrome. Pediatr Dermatol 21:39–43PubMedCrossRef

20.

Nagasawa M, Itoh S, Sawada Y, Morio T, Nonoyama S, Mitzutani S (2004) Coagulopathy in a patient with X-linked hyper-IgM syndrome who developed Kaposi’s sarcoma. Am J Hematol 75:116–117PubMedCrossRef

21.

Kloppel G, Anlauf M (2005) Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 19:507–517PubMedCrossRef

22.

Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S, Cattaruzza MS, Ziparo V, Bordi C, Pederzoli P, Delle Fave G (2005) Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 12:1083–1092PubMedCrossRef

23.

Plockinger U, Wiedenmann B (2005) Endocrine tumours of the gastrointestinal tract. Management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 19:553–576PubMedCrossRef

24.

Schillaci O, Spanu A, Scopinaro F, Falchi A, Corleto V, Danieli R, Marongiu P, Pisu N, Madeddu G, Delle Fave G, Madeddu G (2003) Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors. Int J Oncol 23:1687–1695PubMed

25.

Mitry E, Baudin E, Ducreus M, Sabourin JC, Rufie P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351–1355PubMedCrossRef

26.

Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232PubMedCrossRef

27.

Mitry E, Rougier P (2001) The treatment of undifferentiated neuroendocrine tumors. Crit Rev Oncol Hematol 37:47–51PubMedCrossRef

28.

Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK (2001) Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101–1107PubMedCrossRef

29.

Bajetta E, Procopio G, Ferrari L, Catena L, Del Vecchio M, Bombardieri E (2003) Update on the treatment of neuroendocrine tumors. Expert Rev Anticancer Ther 3:631–642PubMedCrossRef

30.

Della Torre S, Procopio G, Fusi A, Catena L, Ferrari L, Nova P, Denaro A, Bichisao E, Bajetta E (2003) Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy. Tumori 89:111–116PubMed

31.

Ollivier S, Fonck M, Becouarn Y, Brunet R (1998) Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial. Am J Clin Oncol 21:237–240PubMedCrossRef

32.

Arnold R, Rinke A, Schmidt Ch, Hofbauer L (2005) Endocrine tumours of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol 19:649–656PubMedCrossRef

Titel: X-linked Hyper-IgM Syndrome Associated with Poorly Differentiated Neuroendocrine Tumor Presenting as Obstructive Jaundice Secondary to Extensive Adenopathy
verfasst von: Nandini Nagaraj
Chukwuma Egwim
Douglas G. Adler
Publikationsdatum: 01.09.2007
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 9/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-006-9702-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2007

Outcome of ERCP in the Management of Duct-to-Duct Anastomotic Strictures in Orthotopic Liver Transplant

Colonization and Impact of Disease and Other Factors on Intestinal Microbiota

The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver Disease

Hypermethylation of SFRP2 as a Potential Marker for Stool-Based Detection of Colorectal Cancer and Precancerous Lesions

Association Among C-Reactive Protein, Fatty Liver Disease, and Cardiovascular Risk